Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis (NASH) cirrhosis and cancer, announced today that the …